Accurate Clinical Research (United States)
Dose-response effect ofBifidobacterium lactisHN019 on whole gut transit time and functional gastrointestinal symptoms in adults
2011 · Philip A Waller, Pramod K. Gopal, et al. · Scandinavian Journal of Gastroenterology
Ab 0373 Treatment Of Sle With The Immunoproteasome Inhibitor Kzr 616 Results From The First 4 Cohorts Of The Mission Study An Open Label Phase 1 B Dose Escalation Trial
2020 · Richard Furie, Samir V. Parikh, et al. · Annals of the Rheumatic Diseases
P130 Treatment of SLE with the immunoproteasome inhibitor KZR-616: results from the first 4 cohorts of the MISSION study, an open-label phase 1b dose escalation trial
2020 · Richard Furie, Samir V. Parikh, et al. · Poster presentations